Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.

@article{Hong2009PhaseIT,
  title={Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.},
  author={David S. Hong and Said M. Sebti and Robert A. Newman and Michelle A. Blaskovich and Lei Ye and R. F. Gagel and Stacy Moulder and Jennifer J. Wheler and Aung Naing and Nizar M. Tannir and Chaan S. Ng and Steven I. Sherman and Adel K El Naggar and Rabia Khan and Jon Trent and John Joseph Wright and Razelle Kurzrock},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2009},
  volume={15 22},
  pages={7061-8}
}
PURPOSE We evaluated the safety, maximum tolerated dose, pharmacokinetics, and biological effects of the combination of the Raf-1, RET, KIT, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor 2 kinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib. EXPERIMENTAL DESIGN A standard 3 + 3 phase I… CONTINUE READING